Antibody-drug conjugates in precision oncology
Cancer Cell · 2026-06 · 44 (6) · 1126-1146
DOI: 10.1016/j.ccell.2026.05.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-06. Verfasst von Barbara Pistilli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gustave Roussy, Villejuif, France; IHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejui…. Hauptthemen laut MEDLINE: Immunoconjugates, Precision Medicine, Neoplasms, Medical Oncology. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) represent a growing therapeutic class in oncology marked by several transformative clinical successes. However, these exceptional outcomes remain restricted to a limited number of tumor types, and ADC development has been marked by frequent clinical setbacks, underscoring persistent challenges in optimal patient selection, biomarker assay standardization, chemical design, and the limited predictive value of existing preclinical models. Despite broader advances in precision oncology, ADC development has largely occurred without validated biomarkers. Emerging evidence indicates that ADC activity extends beyond target antigen expression alone, encompassing tumor-intrinsic features and tumor microenvironment-dependent processes. This challenges the view of ADCs as strictly targeted agents and supports their conceptualization as tumor-ecosystem-targeting therapies governed by multidimensional biological determinants. In this review, we link ADC successes and setbacks to mechanisms of efficacy, resistance, and toxicity, and discuss how biomarkers, ADC combinations, next-generation platforms, and curative-intent strategies should shape precision oncology frameworks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; IHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France. Electronic address: barbara.pistilli@gustaveroussy.fr.
- ADC Therapeutic Development, Zymeworks Inc., Vancouver, BC, Canada.
- IHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France; INSERM U981, Gustave Roussy, Paris, France; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New Y…
Zitieren
APA
Pistilli, B., Colombo, R., Mosele, M. F., & Chandarlapaty, S. (2026). Antibody-drug conjugates in precision oncology. Cancer Cell, 44(6), 1126-1146. https://doi.org/10.1016/j.ccell.2026.05.004
Vancouver
Pistilli B, Colombo R, Mosele MF, Chandarlapaty S. Antibody-drug conjugates in precision oncology. Cancer Cell. 2026;44(6):1126-1146. doi:10.1016/j.ccell.2026.05.004
BibTeX
@article{Pistilli2026,
author = {Pistilli, Barbara and Colombo, Raffaele and Mosele, Maria Fernanda and Chandarlapaty, Sarat},
title = {Antibody-drug conjugates in precision oncology},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {6},
pages = {1126--1146},
doi = {10.1016/j.ccell.2026.05.004}
}
EUVIMED